X

Trial Profile

A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
Indications Mouth neoplasm; Squamous cell cancer
Focus Therapeutic Use
Acronyms NEOPBOSCC

Most Recent Events

17 Aug 2022 Planned End Date changed from 30 Nov 2023 to 10 Aug 2024.
17 Aug 2022 Status changed from recruiting to active, no longer recruiting.
08 Mar 2022 Planned number of patients changed from 108 to 70.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com